Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Advanced Cancers 1

Interventions

Magnetic Resonance Spectroscopy 56enzalutamide 44Specimen Handling 37apalutamide 35Androgen Antagonists 35Abiraterone Acetate 29Prednisone 27Radiosurgery 26darolutamide 25Docetaxel 23Pluvicto 22abiraterone 21Radiotherapy 21Leuprolide 20Biopsy 16relugolix 14acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 14gallium 68 PSMA-11 12Triptorelin Pamoate 12Surveys and Questionnaires 12Radiation 12Gonadotropin-Releasing Hormone 12X-Rays 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 10cabazitaxel 9bicalutamide 9Standard of Care 9Nivolumab 9Goserelin 9Carboplatin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Sugars × 90 days × Clear all
NCT02064673 2026-03-30

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

University of Texas Southwestern Medical Center

Phase 3 Recruiting
650 enrolled
Genitourinary

Prostatic Neoplasms

NCT05726292 2026-03-04

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

University of Chicago

Phase 2 Recruiting
90 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡